Invention Grant
- Patent Title: Salmeterol superfine formulation
- Patent Title (中): 沙美特罗超细配方
-
Application No.: US10531867Application Date: 2003-06-18
-
Publication No.: US08088362B2Publication Date: 2012-01-03
- Inventor: Tanya Kathleen Church , David Andrew Lewis , David Ganderton , Brian John Meakin , Gaetano Brambilla
- Applicant: Tanya Kathleen Church , David Andrew Lewis , David Ganderton , Brian John Meakin , Gaetano Brambilla
- Applicant Address: IT Parma
- Assignee: Chiesi Farmaceutici S.p.A.
- Current Assignee: Chiesi Farmaceutici S.p.A.
- Current Assignee Address: IT Parma
- Agency: Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P.
- Priority: EP02023589 20021023
- International Application: PCT/EP03/06444 WO 20030618
- International Announcement: WO2004/037227 WO 20040506
- Main IPC: A61K9/12
- IPC: A61K9/12 ; A61K9/00
Abstract:
The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting β2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurized metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Public/Granted literature
- US20060120966A1 Salmeterol superfine formulation Public/Granted day:2006-06-08
Information query
